Medifast Inc
MED NYSE· Miscellaneous Food Preparations & Kindred Products
Last close · Oct 27, 2026
$12.49
KIRA · Stoqly’s AI analyst, in plain words
- Medifast Inc had $386M of revenue in fiscal 2025, down 36.0% on the year before. Over five years, revenue changed −16.2% a year on average.
- Its operating margin was −3.7%, down 4.2 pts: of every 100 in sales, about −4 is left after running the business.
- Medifast Inc lost $18.7M in fiscal 2025.
- Free cash flow was $1.2M in fiscal 2025, 0.3% of revenue.
- Medifast Inc returned $0.2M to shareholders in fiscal 2025, 16% of free cash flow. The diluted share count rose 0.2%.
Market cap
$139M
P/E
—
Revenue
$386M
Net income
−$18.7M
Free cash flow
$1.2M
Operating margin
−3.7%
Medifast Inc in 30 seconds · fiscal 2025
Are sales growing?
−36.0%
No. Sales fell 36.0% last year.
Does it make a profit?
−4.8%
No. It lost money last year.
Does profit turn into cash?
0.3%
Partly. 0.3% of sales ends up as free cash.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Medifast Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- MEDIFAST INC
- CIK
- 0000910329
Medifast Inc · MED
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.5B | $1.6B | $1.1B | $602M | $386M |
| Revenue growth | 63.2% | 4.8% | −32.9% | −43.8% | −36.0% |
| Gross margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Operating margin | 14.2% | 11.6% | 11.8% | 0.5% | −3.7% |
| Net income | $164M | $144M | $99.4M | $2.1M | −$18.7M |
| Net margin | 10.7% | 9.0% | 9.3% | 0.3% | −4.8% |
| Diluted EPS | $13.89 | $12.73 | $9.10 | $0.19 | −$1.70 |
| Cash | |||||
| Cash from operations | $94.5M | $195M | $148M | $24.5M | $6.9M |
| Capital expenditure | $34.2M | $16.7M | $6.5M | $7.5M | $5.6M |
| Free cash flow | $60.3M | $178M | $141M | $17.0M | $1.2M |
| FCF margin | 4.0% | 11.1% | 13.2% | 2.8% | 0.3% |
| Dividends paid | $63.9M | $71.6M | $73.0M | $0.7M | $0.2M |
| Share buybacks | $56.0M | $126M | $3.6M | $0.0M | $0.0M |
| Share count change | −0.3% | −4.5% | −3.1% | 0.4% | 0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $110M | $87.7M | $150M | $162M | $167M |
| Shareholders' equity | $202M | $155M | $201M | $210M | $199M |
| Current ratio | 1.8x | 1.6x | 2.4x | 3.3x | 4.7x |
| Returns and quality | |||||
| Return on equity | 91.2% | 80.3% | 55.8% | 1.0% | −9.1% |
| Return on tangible equity | 81.0% | 92.6% | 49.3% | 1.0% | −9.4% |
| Piotroski F-score | 5 | 6 | 6 | 5 | 3 |
| Altman Z'' | 8.5 | 8.1 | 9.3 | 8.5 | 10.2 |
Insiders bought, 12 months
$1.7M
3 insiders
Insiders sold, 12 months
$0.2M
1 insider
Of sales under plans
100%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Medifast Inc · MED
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.49 a share, the company is worth $139M.
Source: SEC EDGAR XBRL filings (CIK 0000910329). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.